Comparison of the diagnostic accuracy of three commercially available enzyme immunoassays for anti-p53 antibodies

Clinical Chemistry

Volumn 45, Issue 11, 1999, Pages 2014-2016

  Rohayem, Jacques ^a   Conrad, Karsten ^a   Zimmermann, Thomas ^a   Frank, Karl Heinz ^a  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; PROTEIN P53;

ADULT; AGED; ANTIBODY DETECTION; AREA UNDER THE CURVE; ARTICLE; CANCER DIAGNOSIS; CLASSIFICATION; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; ENZYME IMMUNOASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE;

EID: 0032753331     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1093/clinchem/45.11.2014     Document Type: Article

References (21)

1. 1. Marxsen J, Schmiegel W, Röder C, Harder R, Juhl H, Kalthoff H, et al. Detection of the anti-p53 antibody response in malignant and benign pancreatic disease. Br J Cancer 1994;70:1031-4.
2. 2. Velculescu VE, El-Deiry WS. Biological and clinical importance of the p53 tumor suppressor gene. Clin Chem 1996;42:858-68.
3. 3. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science 1991;253:49-53.
4. 4. Levine AJ, Momand J, Finley CA. The p53 tumor suppressor gene. Nature 1991;351:453-6.
5. 5. Harris CC, Hollstein M. Clinical implications of the p53 tumor suppressor gene. N Engl J Med 1993;329:1318-27.
6. 6. Schlichtholz B, Legros Y, Gillet D, Gaillard C, Marty M, Soussi T. The immune response to p53 in breast cancer patients is directed against immunodominant epitopes unrelated to the mutational hotspot. Cancer Res 1992;52: 6380-4.
7. 7. Labrecque S, Naor N, Thomson D, Mathlashewski G. Analysis of the anti-p53 antibody response in cancer patients. Cancer Res 1993;53:3468-71.
8. 8. Angelopoulou K, Diamandis EP, Sutherland DJ, Kellen JA, Bunting PS. Prevalence of serum antibodies against the p53 tumor suppressor gene protein in various cancers. Int J Cancer 1994;58:480-7.
9. 9. Soussi T, Lubin R. Anti-p53 antibodies. In: Peter JB, Shoenfeld Y, eds. Antibodies. New York: Elsevier Science, 1996:595-9.
10. 10. Winter SF, Minna JD, Johnson BE, Takahashi T, Gazdar AF, Carbone DP. Development of antibodies against p53 in lung cancer patients appears to be dependent on the p53 mutation. Cancer Res 1992;52:4168-74.
11. 11. Green JA, Mundela B, Jenkins J, Leinster SJ, Tarunima M, Green B, et al. Serum p53 antibodies: incidence in familial breast cancer. Eur J Cancer 1994;30:580-4.
12. 12. Davidoff AM, Igelhart JD, Marks JR. Immune response to p53 is dependent upon p53/HSP70 complexes in breast cancers. Proc Natl Acad Sci U S A 1992;89:3439-42.
13. 13. Volkmann M, Muller M, Hofmann WJ, Meyer M, Hagelstein J, Rath U, et al. The humoral immune response to p53 in patients with hepatocellular carcinoma is specific for malignancy and independent of the alpha-fetoprotein status. Hepatology 1993;18:559-65.
14. 14. Angelopoulou K, Stratis M, Diamandis P. Humoral immune response against p53 protein in patients with colorectal carcinoma. Int J Cancer 1997;70: 46-51.
15. 15. Lubin R, Schlichtholz B, Teillaid JL, Garay E, Bussel A, Wild CP, et al. p53 antibodies in patients with various types of cancer: assay, identification, and characterization. Clin Cancer Res 1995;1:1463-9.
16. 16. Lubin R, Zalcman G, Bouchet L. Serum p53 antibodies as early markers of lung cancer. Nat Med 1995;1:701-2.
17. 17. Zweig MH, Campbell G. Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. Clin Chem 1993;39:561-77.
18. 18. National Committee for Clinical Laboratory Standards. User evaluation of the precision performance of clinical chemistry devices. Tentative Guideline EP5-T2. Wayne, PA: NCCLS, 1992.
19. 19. Cornbleet PJ, Gochman N. Incorrect least-squares regression coefficients in method comparison analysis. Clin Chem 1979;25:432-8.
20. 20. Davies C. Technical performance concepts. In: Wild D, ed. The immunoassay handbook. New York: Stockton Press, 1994:83-99.
21. 21. National Committee for Clinical Laboratory Standards. Interference testing in clinical chemistry. Proposed Guideline EP7-P. Villanova, PA: NCCLS, 1986.